Search

Your search keyword '"Dekken, H. van"' showing total 19 results
Start Over Author "Dekken, H. van" Publication Year Range Last 50 years
19 results on '"Dekken, H. van"'

1. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of BarrettEs oesophagus: a randomized trial

Author

Hage, M., Siersema, P.D., Dekken, H. van, Steyerberg, E.W., Haringsma, J., Vrie, W. van de, Grool, T.E., Veen, R.L.P. van, Sterenborg, H.J.C.M., and Kuipers, E.J.

Subjects
Epithelium -- Care and treatment, Photochemotherapy -- Comparative analysis, Medical research, Medicine, Experimental, Health
Abstract

A study is conducted with the aim to compare 5-aminolevulinic acid induced photodynamic therapy (ALA-PDT) with argon plasma coagulation (APC) with respect to complete reversal of BarrettEs oesophagus (BO). The administration of APC or ALA-PDT in combination with APC in multiple treatment sessions results in complete reversal of BarrettEs epithelium in nearly two third of the patients.

Published
2004

3. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

Author

Hagen, P. van, Hulshof, M.C.C., Lanschot, J.J. van, Steyerberg, E.W., Berge Henegouwen, M.I. van, Wijnhoven, B.P., Richel, D.J., Nieuwenhuijzen, G.A., Hospers, G.A., Bonenkamp, J.J., Cuesta, M.A., Blaisse, R.J., Busch, O.R., Kate, F.J. ten, Creemers, G.J., Punt, C.J.A., Plukker, J.T., Verheul, H.M., Spillenaar Bilgen, E.J., Dekken, H. van, Sangen, M.J. van der, Rozema, T., Biermann, K., Beukema, J.C., Piet, A.H., Rij, C.M. van, Reinders, J.G., Tilanus, H.W., Gaast, A. van der, Krieken, J.H. van, CCA -Cancer Center Amsterdam, Radiotherapy, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Oncology, Other departments, Gastroenterology and Hepatology, Pathology, Medical oncology, Radiation Oncology, CCA - Innovative therapy, Public Health, Medical Oncology, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Targeted Gynaecologic Oncology (TARGON)

Subjects
Male, Esophageal Neoplasms, SURGERY, medicine.medical_treatment, Kaplan-Meier Estimate, Carboplatin, CHEMORADIATION, chemistry.chemical_compound, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant therapy, Immune Regulation Translational research [NCMLS 2], Hazard ratio, PHASE-III TRIAL, General Medicine, Middle Aged, Translational research Tissue engineering and pathology [ONCOL 3], Neoadjuvant Therapy, SURVIVAL, Adenocarcinoma, Female, Esophagogastric Junction, RADIOTHERAPY, Adult, medicine.medical_specialty, CARCINOMA, Paclitaxel, Preoperative care, Quality of Care [ONCOL 4], Invasive mycoses and compromised host [N4i 2], CISPLATIN, SDG 3 - Good Health and Well-being, Translational research [ONCOL 3], Preoperative Care, medicine, Carcinoma, Humans, Aged, business.industry, PERIOPERATIVE CHEMOTHERAPY, ADENOCARCINOMA, Chemoradiotherapy, Adjuvant, medicine.disease, Surgery, Regimen, chemistry, WEEKLY PACLITAXEL, business, Chemoradiotherapy, Follow-Up Studies
Abstract

Contains fulltext : 109134.pdf (Publisher’s version ) (Closed access) BACKGROUND: The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population. METHODS: We randomly assigned patients with resectable tumors to receive surgery alone or weekly administration of carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week), followed by surgery. RESULTS: From March 2004 through December 2008, we enrolled 368 patients, 366 of whom were included in the analysis: 275 (75%) had adenocarcinoma, 84 (23%) had squamous-cell carcinoma, and 7 (2%) had large-cell undifferentiated carcinoma. Of the 366 patients, 178 were randomly assigned to chemoradiotherapy followed by surgery, and 188 to surgery alone. The most common major hematologic toxic effects in the chemoradiotherapy-surgery group were leukopenia (6%) and neutropenia (2%); the most common major nonhematologic toxic effects were anorexia (5%) and fatigue (3%). Complete resection with no tumor within 1 mm of the resection margins (R0) was achieved in 92% of patients in the chemoradiotherapy-surgery group versus 69% in the surgery group (P

Published
2012
Full Text
View/download PDF

4. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Author

Shapiro, J., Lanschot, J.J. van, Hulshof, M.C.C., Hagen, P. van, Berge Henegouwen, M.I. van, Wijnhoven, B.P., Laarhoven, H.W.M. van, Nieuwenhuijzen, G.A., Hospers, G.A., Bonenkamp, J.J., Cuesta, M.A., Blaisse, R.J., Busch, O.R., Kate, F.J. ten, Creemers, G.J., Punt, C.J.A., Plukker, J.T., Verheul, H.M., Bilgen, E.J., Dekken, H. van, Sangen, M.J. van der, Rozema, T., Biermann, K., Beukema, J.C., Piet, A.H., Rij, C.M van, Reinders, J.G., Tilanus, H.W., Steyerberg, E.W., Gaast, A. van der, Shapiro, J., Lanschot, J.J. van, Hulshof, M.C.C., Hagen, P. van, Berge Henegouwen, M.I. van, Wijnhoven, B.P., Laarhoven, H.W.M. van, Nieuwenhuijzen, G.A., Hospers, G.A., Bonenkamp, J.J., Cuesta, M.A., Blaisse, R.J., Busch, O.R., Kate, F.J. ten, Creemers, G.J., Punt, C.J.A., Plukker, J.T., Verheul, H.M., Bilgen, E.J., Dekken, H. van, Sangen, M.J. van der, Rozema, T., Biermann, K., Beukema, J.C., Piet, A.H., Rij, C.M van, Reinders, J.G., Tilanus, H.W., Steyerberg, E.W., and Gaast, A. van der

Abstract

Item does not contain fulltext, BACKGROUND: Initial results of the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) comparing neoadjuvant chemoradiotherapy plus surgery versus surgery alone in patients with squamous cell carcinoma and adenocarcinoma of the oesophagus or oesophagogastric junction showed a significant increase in 5-year overall survival in favour of the neoadjuvant chemoradiotherapy plus surgery group after a median of 45 months' follow-up. In this Article, we report the long-term results after a minimum follow-up of 5 years. METHODS: Patients with clinically resectable, locally advanced cancer of the oesophagus or oesophagogastric junction (clinical stage T1N1M0 or T2-3N0-1M0, according to the TNM cancer staging system, sixth edition) were randomly assigned in a 1:1 ratio with permuted blocks of four or six to receive either weekly administration of five cycles of neoadjuvant chemoradiotherapy (intravenous carboplatin [AUC 2 mg/mL per min] and intravenous paclitaxel [50 mg/m(2) of body-surface area] for 23 days) with concurrent radiotherapy (41.4 Gy, given in 23 fractions of 1.8 Gy on 5 days per week) followed by surgery, or surgery alone. The primary endpoint was overall survival, analysed by intention-to-treat. No adverse event data were collected beyond those noted in the initial report of the trial. This trial is registered with the Netherlands Trial Register, number NTR487, and has been completed. FINDINGS: Between March 30, 2004, and Dec 2, 2008, 368 patients from eight participating centres (five academic centres and three large non-academic teaching hospitals) in the Netherlands were enrolled into this study and randomly assigned to the two treatment groups: 180 to surgery plus neoadjuvant chemoradiotherapy and 188 to surgery alone. Two patients in the neoadjuvant chemoradiotherapy group withdrew consent, so a total of 366 patients were analysed (178 in the neoadjuvant chemoradiotherapy plus surgery group and 188 in the surgery alone group). Of 171

Published
2015

5. Long-term survival after resection for non-pancreatic periampullary cancer followed by adjuvant intra-arterial chemotherapy and concomitant radiotherapy

Author

Erdmann, J.I., Morak, M.J.M., Duivenvoorden, H.J., Dekken, H. van, Kazemier, G., Kok, N.F., Eijck, C.H. van, Erdmann, J.I., Morak, M.J.M., Duivenvoorden, H.J., Dekken, H. van, Kazemier, G., Kok, N.F., and Eijck, C.H. van

Abstract

Item does not contain fulltext, BACKGROUND: There is no consensus regarding the optimal adjuvant treatment after resection of non-pancreatic periampullary adenocarcinoma (NPPC; distal common bile duct, ampulla, duodenum). OBJECTIVES: The present study was conducted to evaluate the impacts on longterm survival and recurrence of adjuvant intra-arterial chemotherapy (IAC) and concomitant radiotherapy (RT) in patients submitted to resection for NPPC or pancreatic ductal adenocarcinoma (PDAC) in a randomized controlled trial. METHODS: A total of 120 patients with PDAC (n = 62) or NPPC (n = 58) were prestratified at a ratio of 1:1 for tumour origin and randomized. Half of these patients were treated with adjuvant IAC/RT and the other half were treated with surgery alone. Follow-up was completed for all patients up to 5 years after resection or until death. Results : There was no survival benefit in either the whole group (primary endpoint) or the PDAC group after IAC/RT. In the NPPC group, longterm survival was observed in 10 patients in the IAC/RT group and five patients in the control group: median survival was 37 months and 28 months, respectively. The occurrence of liver metastases was reduced by IAC/RT from 57% to 29% (P = 0.038). Cox regression analysis revealed a substantial effect of IAC/RT on survival (hazard ratio: 0.44, 95% confidence interval 0.23-0.83; P = 0.011). CONCLUSIONS: This longterm analysis shows that median and longterm survival were improved after IAC/RT in patients with NPPC, probably because of the effective and sustained reduction of liver metastases. The present results illustrate that NPPC requires an adjuvant approach distinct from that in pancreatic cancer and indicate that further investigation of this issue is warranted.

Published
2015

6. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.

Author

Koen Talsma, A., Shapiro, J., Looman, C.W., Hagen, P. van, Steyerberg, E.W., Gaast, A. van der, Berge Henegouwen, M.I. van, Wijnhoven, B.P., Lanschot, J.J. van, Hulshof, M.C.C., Laarhoven, H.W.M. van, Nieuwenhuijzen, G.A., Hospers, G.A., Bonenkamp, J.J., Cuesta, M.A., Blaisse, R.J., Busch, O.R., Kate, F.J. ten, Creemers, G.J., Punt, C.J.A., Plukker, J.T., Verheul, H.M., Dekken, H. van, Sangen, M.J. van der, Rozema, T., Biermann, K., Beukema, J.C., Piet, A.H., Rij, C.M van, Reinders, J.G., Tilanus, H.W., Koen Talsma, A., Shapiro, J., Looman, C.W., Hagen, P. van, Steyerberg, E.W., Gaast, A. van der, Berge Henegouwen, M.I. van, Wijnhoven, B.P., Lanschot, J.J. van, Hulshof, M.C.C., Laarhoven, H.W.M. van, Nieuwenhuijzen, G.A., Hospers, G.A., Bonenkamp, J.J., Cuesta, M.A., Blaisse, R.J., Busch, O.R., Kate, F.J. ten, Creemers, G.J., Punt, C.J.A., Plukker, J.T., Verheul, H.M., Dekken, H. van, Sangen, M.J. van der, Rozema, T., Biermann, K., Beukema, J.C., Piet, A.H., Rij, C.M van, Reinders, J.G., and Tilanus, H.W.

Abstract

1 november 2014, Item does not contain fulltext, OBJECTIVES: We aimed to examine the association between total number of resected nodes and survival in patients after esophagectomy with and without nCRT. BACKGROUND: Most studies concerning the potentially positive effect of extended lymphadenectomy on survival have been performed in patients who underwent surgery alone. As nCRT is known to frequently "sterilize" regional nodes, it is unclear whether extended lymphadenectomy after nCRT is still useful. METHODS: Patients from the randomized CROSS-trial who completed the entire protocol (ie, surgery alone or chemoradiotherapy + surgery) were included. With Cox regression models, we compared the impact of number of resected nodes as well as resected positive nodes on survival in both groups. RESULTS: One hundred sixty-one patients underwent surgery alone, and 159 patients received multimodality treatment. The median (interquartile range) number of resected nodes was 18 (12-27) and 14 (9-21), with 2 (1-6) and 0 (0-1) resected positive nodes, respectively. Persistent lymph node positivity after nCRT had a greater negative prognostic impact on survival as compared with lymph node positivity after surgery alone. The total number of resected nodes was significantly associated with survival for patients in the surgery-alone arm (hazard ratio per 10 additionally resected nodes, 0.76; P=0.007), but not in the multimodality arm (hazard ratio 1.00; P=0.98). CONCLUSIONS: The number of resected nodes had a prognostic impact on survival in patients after surgery alone, but its therapeutic value is still controversial. After nCRT, the number of resected nodes was not associated with survival. These data question the indication for maximization of lymphadenectomy after nCRT.

Published
2014

7. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors

Author

Looijenga, L.H.J., Stoop, H., Leeuw, H.P.J.C. de, Gouveia Brazao, C.A. De, Gillis, A.J.M., Roozendaal, C.E.P. van, Zoelen, E.J.J. van, Weber, R.F.A., Wolffenbuttel, K.P., Dekken, H. van, Honecker, F., Bokemeyer, C., Perlman, E.J., Kononen, J., Sauter, G., and Oosterhuis, J.W.

Subjects
Cell Biology
Abstract

Item does not contain fulltext

Published
2003

9. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

Author

Hulscher, J.B.F., Sandick, J.W. van, Boer, A.G.E.M. de, Wijnhoven, B.P., Tijssen, J.G.P., Fockens, P., Stalmeier, P.F.M., Kate, F.J. ten, Dekken, H. van, Obertop, H., Tilanus, H.W., Lanschot, J.J. van, Hulscher, J.B.F., Sandick, J.W. van, Boer, A.G.E.M. de, Wijnhoven, B.P., Tijssen, J.G.P., Fockens, P., Stalmeier, P.F.M., Kate, F.J. ten, Dekken, H. van, Obertop, H., Tilanus, H.W., and Lanschot, J.J. van

Abstract

Item does not contain fulltext, BACKGROUND: Controversy exists about the best surgical treatment for esophageal carcinoma. METHODS: We randomly assigned 220 patients with adenocarcinoma of the mid-to-distal esophagus or adenocarcinoma of the gastric cardia involving the distal esophagus either to transhiatal esophagectomy or to transthoracic esophagectomy with extended en bloc lymphadenectomy. Principal end points were overall survival and disease-free survival. Early morbidity and mortality, the number of quality-adjusted life-years gained, and cost effectiveness were also determined. RESULTS: A total of 106 patients were assigned to undergo transhiatal esophagectomy, and 114 to undergo transthoracic esophagectomy. Demographic characteristics and characteristics of the tumor were similar in the two groups. Perioperative morbidity was higher after transthoracic esophagectomy, but there was no significant difference in in-hospital mortality (P=0.45). After a median follow-up of 4.7 years, 142 patients had died--74 (70 percent) after transhiatal resection and 68 (60 percent) after transthoracic resection (P=0.12). Although the difference in survival was not statistically significant, there was a trend toward a survival benefit with the extended approach at five years: disease-free survival was 27 percent in the transhiatal-esophagectomy group, as compared with 39 percent in the transthoracic-esophagectomy group (95 percent confidence interval for the difference, -1 to 24 percent [the negative value indicates better survival with transhiatal resection]), whereas overall survival was 29 percent as compared with 39 percent (95 percent confidence interval for the difference, -3 to 23 percent). CONCLUSIONS: Transhiatal esophagectomy was associated with lower morbidity than transthoracic esophagectomy with extended en bloc lymphadenectomy. Although median overall, disease-free, and quality-adjusted survival did not differ statistically between the groups, there was a trend toward improved long-term surviv

Published
2002

14. Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid.

Author

Hinnen, P, Rooij, F W M de, Terlouw, E M, Edixhoven, A, Dekken, H van, Hillegersberg, R van, Tilanus, H W, Wilson, J H P, Siersema, P D, de Rooij, F W, van Dekken, H, van Hillegersberg, R, and Wilson, J H

Subjects
PORPHYRINS, ESOPHAGUS diseases, ENZYME metabolism, ADENOCARCINOMA, AMINO acids, COMPARATIVE studies, ESOPHAGEAL tumors, HETEROCYCLIC compounds, RESEARCH methodology, MEDICAL cooperation, ORAL drug administration, PHOTOCHEMOTHERAPY, PHOTOSENSITIZERS, RESEARCH, TRANSFERASES, EVALUATION research, BARRETT'S esophagus, METALLOPORPHYRINS, PHARMACODYNAMICS
Abstract

5-Aminolaevulinic acid (ALA)-induced porphyrin biosynthesis, which is used for ALA-based photodynamic therapy (ALA-PDT), was studied in tissues of 10 patients with Barrett's oesophagus (BE) and adenocarcinoma of the oesophagus (AC) undergoing oesophagectomy at a mean time interval of 6.7 h after the ingestion of ALA (60 mg kg(-1)). In BE, AC, squamous epithelium (SQ) and gastric cardia, the activities of the haem biosynthetic enzymes porphobilinogen deaminase (PBG-D) and ferrochelatase (FC) and the PDT power index--the ratio between PBG-D and FC in BE and AC in comparison with SQ--were determined before ALA ingestion. Following ALA administration, ALA, porphobilinogen, uroporphyrin I and PPIX were determined in tissues and plasma. The PDT power index did not predict the level of intracellular accumulation of PPIX found at 6.7 h. In BE, there was no selectivity of PPIX accumulation compared to SQ, whereas in half of patients with AC selectivity was found. Higher haem biosynthetic enzyme activities (i.e. PBG-D) and lower PPIX precursor concentrations were found in BE and AC compared to SQ. It is therefore possible that PPIX levels will peak at earlier time intervals in BE and AC compared to SQ. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

15. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias

Author

Zondervan, P. E., Wink, J., Alers, J. C., IJzermans, J. N., Schalm, S. W., Man, R. A. de, and Dekken, H. van

Abstract

The worldwide incidence of hepatocellular carcinoma (HCC) is approximately one million cases a year. This makes HCC one of the most frequent human malignancies, especially in Asia and Africa, although the incidence is increasing also in the western world. HCC is a complication of chronic liver disease, with cirrhosis as the most important risk factor. Viral co-pathogenesis makes cirrhosis due to hepatitis B (HBV) and hepatitis C virus (HCV) infection a very important factor in the development of HCC. As curative therapy is often ruled out due to the late detection of HCC, it would be attractive to find parameters which predict malignant transformation in HBV- and HCV-infected livers. This study has used comparative genomic hybridization (CGH) to analyse 26 HCCs (11 non-viral, nine HBV, six HCV) and 12 concurrent dysplasias (five non-viral, five HBV, two HCV). Frequent gain (≥25% of all tumours) was detected, in decreasing order of frequency, on 8q (69%), 1q (46%), 17q (46%), 12q (42%), 20q (31%), 5p (27%), 6q (27%), and Xq (27%). Frequent loss (≥25% of all tumours) was found, in decreasing order of frequency, on 8p (58%), 16q (54%), 4q (42%), 13q (39%), 1p (35%), 4p (35%), 16p (35%), 18q (35%), 14q (31%), 17p (31%), 9p (27%), and 9q (27%). Minimal overlapping regions could be determined at multiple locations (candidate genes in parentheses). Minimal regions of overlap for deletions were assigned to 4p14–15 (PCDH7), 8p21–22 (FEZ1), 9p12–13, 13q14–31 (RB1), 14q31 (TSHR), 16p12–13.1 (GSPT1), 16q21–23 (CDH1), 17p12–13 (TP53), and 18q21–22 (DPC4, DCC). Minimal overlapping amplified sites could be seen at 8q24 (MYC), 12q15–21 (MDM2), 17q22–25 (SSTR2, GH1), and 20q12–13.2 (MYBL2, PTPN1). A single high level amplification was seen on 5q21 in an HBV-related tumour. Aberrations appeared more frequent in HBV-related HCCs than in HCV-associated tumours (p=0.008). This was most prominent with respect to losses (p=0.004), specifically loss on 4p (p=0.007), 16q (p=0.04), 17p (p=0.04), and 18q (p=0.03). In addition, loss on 17p was significantly lower in non-viral cancers than in HBV-related HCC (p<0.001). Furthermore, loss on 13q was more prevalent in HCCs in non-cirrhotic livers (p=0.02), thus suggesting a different, potentially more aggressive, pathway in neoplastic progression. A tendency (p=0.07) was observed for loss on 9q in high-stage tumours; no specific changes were found in relation to tumour grade. A subset of the HCC-associated genetic changes was disclosed in the preneoplastic stage, i.e. liver cell dysplasia. This group of dysplasias showed frequent gain on 17q (25%) and frequent loss on 16q (33%), 4q (25%), and 17p (25%). The majority of the dysplasias with alterations revealed genetic changes that were also present in the primary tumour. In conclusion, firstly, this study has provided a detailed map of genomic changes occurring in HCC of viral and non-viral origin, and has suggested candidate genes. Loss on 17p, including the TP53 region, appeared significantly more prevalent in HBV-associated liver cancers, whereas loss on 13q, with possible involvement of RB1, was distinguished as a possible genetic biomarker. Secondly, CGH analysis of liver cell dysplasia, both viral and non-viral, has revealed HCC-specific early genetic changes, thereby confirming its preneoplastic nature. Finally, genes residing in these early altered regions, such as CDH1 or TP53, might be associated with hepatocellular carcinogenesis. Copyright © 2000 John Wiley & Sons, Ltd. List of abbreviations: protocadherin 7 (PCDH7); F37 oesophageal cancer-related leucine-zipper motif (FEZ1); v-myc oncogene (MYC); mouse double minute 2 (p53 binding protein) (MDM2); retinoblastoma 1 (RB1); thyroid stimulating hormone receptor (TSHR); G1 to S-phase transition 1 (GSPT1); cadherin 1 (E-cadherin) (CDH1); tumour protein p53 (TP53); somatostatin receptor 2 (SSTR2); growth hormone 1 (GH1); deleted in pancreatic carcinoma (DPC4); deleted in colorectal carcinoma (DCC); v-myb myeloblastosis-like oncogene 2 (MYBL2); protein tyrosine phosphatase non-receptor type 1 (PTPN1).

Published
2000

16. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridization

Author

Dekken, H. van, Vissers, C. J., Tilanus, H. W., and Tanke, H. J.

Abstract

Oesophageal adenocarcinomas arising in Barrett's epithelium occasionally present as multiple lesions. This could be due to either a multifocal presentation of the same tumour, or different neoplasms arising simultaneously in a dysplastic Barrett's oesophagus (‘field cancerization’). This is a report of the genetic analysis of multiple neoplastic sites in a Barrett's oesophagus with an extensive area of dysplasia. In addition, the dysplastic Barrett's epithelium was evaluated. For the genetic screening, comparative genomic hybridization (CGH) allowed evaluation of the whole genome of each specimen. Five cancerous regions were selected and subsequently dissected from paraffin-embedded tissue blocks. The use of archival materials enabled a targeted collection of representative tumour locations. Multiple genetic aberrations were detected by CGH in all cancer sites. Losses on 3p, 4, 7q, 18q, and Y, as well as gains on 8q, 9q, 12p, 13q, 17q, 20p and X, were found in each specimen. In four out of the five lesions, simultaneous losses on 9p, 15q, and 16q, with concomitant gains on 5p, 7q, and 10p, were disclosed by CGH. Adjacent high-grade dysplastic Barrett's mucosa shared the losses on 3p, 4, 7q, 9p, 18, and Y, as well as the gains on 5p, 7q, 13q, 17q, and X, thereby confirming its precursor status. Within this single and rare case of multifocal Barrett's adenocarcinoma, a monoclonal genotype was present. This must have been caused by an extensive outgrowth of a single tumour. Copyright © 1999 John Wiley & Sons, Ltd.

Published
1999

17. The Human C/EBPδ (CRP3/CELF) Gene: Structure and Chromosomal Localization

Author

Cleutjens, C. B.J.M., Eekelen, C. C.E.M. van, Dekken, H. van, Smit, E. M.E., Hagemeuer, A., Wagner, M. J., Wells, D. E., and Trapman, J.

Abstract

In an attempt to identify C/EBP-like transcription factors expressed in the prostate, a cDNA homologous to the mouse C/EBPδ (CRP3) and the rat CELF gene was isolated. A genomic clone containing the entire C/EBPδ gene was isolated using a cDNA fragment as a probe. The gene was characterized by restriction mapping and sequence analysis. By fluorescence in situ hybridization, using tile biotinylated genomic clone as a probe, the C/EBPδ gene was assigned to the pericentromeric region of human chromosome 8, most probably to 8q11. This chromosomal localization was confirmed by analysis of a panel of human x hamster somatic cell hybrid DNA samples with a C/EBPδ-specific STS. As a result, the C/EBPδ gene could be positioned between the PLAT and the MOS loci. Copyright 1993, 1999 Academic Press

Published
1993
Full Text
View/download PDF

18. In situ hybridization as a tool in cytogenetics

Author

Dekken, H. van, Instituut voor Toegepaste Radiobiologie en Immunologie TNO, and TU Delft, Delft University of Technology

Subjects
Cell biology, Genetics, Biology
Published
1989

Catalog

Books, media, physical & digital resources
See catalog results